New study shows Weedingtech’s foamstream technology as effective as conventional more pollutant weed killers
Foamstream performs as well as glyphosate, representing an environmentally friendly and effective alternative method to control weeds.
Foamstream performs as well as glyphosate, representing an environmentally friendly and effective alternative method to control weeds.
Invizius has announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology.
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
Calculus has delivered an average ROI of 2.1x from Genedrive plc (AIM: GDR) through a number of exits in the VCT and EIS Funds. Genedrive, a company we had supported through scale-up, was founded as a contract research business (”CRO”) but refocussed as a Point of Care molecular diagnostics company. The company has developed and launched … Continued
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that it has raised £3.2 million
Calculus portfolio company Wonderhood Studios will be working with MADE to help creatively bring to life the brand’s vision, giving it a fresh and bold point of view
Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no different. Our investment team has completed two exits, three investments and are building up a considerable pipeline for Q2. As popularity for VCTs across the board has continued to … Continued
Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.
Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products, AT247 and AT278.